SCHEMBL24793704

SCHEMBL24793704

CN1CCC(n2c(=O)oc3cc(C4CCN(C(=O)OC(C)(C)C)CC4)ccc32)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ASAH1 Q13510 8/20 0.48
FAAH O00519 1/20 0.48
NAAA Q02083 1/20 0.48
NAMPT P43490 1/20 0.45
THRB P10828 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
PDE4B Q07343 1/20 0.41
HSD11B1 P28845 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
JAK1 P23458 1/20 0.40
TP53 P04637 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24793547 0.86 ALDH1A1 (0.49) ASAH1FAAHNAAANAMPTTHRB
SCHEMBL23122135 0.86 ASAH1 (0.53) ASAH1FAAHNAAAHSD11B1
SCHEMBL23541035 0.81 DDB1 (0.54) ASAH1FAAHNAAANAMPTTHRB
SCHEMBL31333843 0.80 DDB1 (0.50) NAMPTTHRBKDM4EMAPTGPR119
SCHEMBL2606334 0.80 HSD11B1 (0.57) KDM4EGPR119HSD11B1
SCHEMBL29709721 0.80 THRB (0.48) ASAH1NAMPTTHRBKDM4EMAPT
SCHEMBL24793705 0.80 THRB (0.48) ASAH1NAMPTTHRBKDM4EMAPT
SCHEMBL24792723 0.78 ASAH1 (0.48) ASAH1FAAHNAAA
Hydrochloric Acid SCHEMBL23122722 0.77 ASAH1 (0.48) ASAH1FAAHNAAA
SCHEMBL31333904 0.76 DDB1 (0.47) ASAH1FAAHNAAANAMPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL R&D INVEST S A (PT) 2022-12-22 US disclosed
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS BIAL R&D INVEST S A (PT) 2022-12-22 US disclosed
EP-4031535-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
CN-114761386-A Substituted N-heterocyclic carboxamides as acid ceramidase inhibitors and their use as pharmaceuticals 比亚尔R&D投资股份公司 2022-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402901-A1 SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS ASAH2, ASAH1, GBA1 ASAH1 2/4885FAAH 65/4885NAAA 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.